Summit Therapeutics
SMMT · NASDAQ
$16.09+$0.52 (+3.34%)TodayMarket closed ·
Prev close $15.57
EPS: actual vs estimate
Beat the estimate in 3 of the last 8 quarters, by 2.8% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- -$0.22
- Revenue estimate
- $54.00K
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.2849 | -$0.28 | +1.7% |
| Q1 FY26 | -$0.1801 | -$0.24 | −33.3% |
| Q4 FY25 | -$0.0656 | -$0.29 | −342.1% |
| Q3 FY25 | -$0.1345 | -$0.31 | −130.5% |
| Q2 FY25 | -$0.0964 | -$0.12 | −24.5% |
| Q1 FY25 | -$0.0928 | -$0.09 | +3.0% |
| Q4 FY24 | -$0.0831 | -$0.08 | +3.7% |
| Q3 FY24 | -$0.068 | -$0.08 | −17.6% |
Earnings calls
- SMMT - Earnings call Q2 2026
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Special Call - Summit Therapeutics Inc.
- The Citizens Life Sciences Conference 2026
- TD Cowen 46th Annual Health Care Conference
- SMMT - Earnings call Q4 2025
- 44th Annual J.P. Morgan Healthcare Conference
- Evercore 8th Annual Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.